In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported ...

Pfizer's payout ratio is around 90% of earnings, which is high for a dividend stock. It reported strong operational growth of ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Pfizer's free cash flow should improve. The drugmaker's lower leverage ratio target gives it greater financial flexibility.

Scientists in Turkey found that the Pfizer COVID-19 vaccine impacted some people's corneas, according to a study.

Pfizer is advancing research and building a comprehensive "toolbox" for Vietnamese patients, combining innovative vaccines, ...